Lorus Therapeutics Appoints Dr. Brad Thompson, an Experienced Biotechnology
Professional, to the Board of Directors
TORONTO, ONTARIO -- (Marketwired) -- 06/27/13 -- Lorus Therapeutics
Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical
company specializing in the research and development of
pharmaceutical products and technologies for the management of
cancer, today announced that Dr. Brad Thompson has been appointed to
the Board of Directors of Lorus.
Dr. Thompson is an experienced and respected biotechnology
professional who has held the positions of Chairman of the Board and
President and Chief Executive Officer of Oncolytics Biotech Inc.
since April 1999. Prior to his role with Oncolytics Dr. Thompson was
the Chief Executive Officer of Synsorb Biotech from 1994 to 1999. Dr.
Thompson is also currently a board member of Immunovaccine Inc. He
received his PhD from the University of Western Ontario in the
Department of Microbiology and Immunology.
"We are delighted that Dr. Thompson is joining our Board," said Dr.
Jim Wright, Chairman of the Board of Directors of Lorus. "We believe
that Brad's depth of experience and success in developing and
financing biotechnology companies will be a significant asset to
Lorus and we look forward to benefiting from his expertise."
"I am very pleased to be joining the Lorus Board of Directors and
contributing to the company's future success in developing new drugs
for the treatment of cancer," Dr. Thompson commented.
Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory
expertise by developing new drug candidates that can be used, either
alone, or in combination with other drugs, to successfully manage
cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to: the ability
of the company to continue as a going concern, the ability to find
future financing, the Company's plans, objectives, expectations and
intentions and other statements including words such as "continue",
"expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with
respect to future events and are subject to risks and uncertainties
and are necessarily based upon a number of estimates and assumptions
that, while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our actual
results, performance or achievements to be materially different from
any future results, performance or achievements described in this
press release. Such expressed or implied forward-looking statements
could include, among others: our ability to continue to operate as a
going concern; our ability to obtain the capital required for
research and operations; the inherent risks in early stage drug
development including demonstrating efficacy; development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with potential
partners; our ability to attract and retain key personnel; changing
market conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the United
States Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled "Risk Factors"
in our filings with Canadian securities regulators and the United
States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do
not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot
assure you that such statements will prove to be accurate as actual
results and future events could differ materially from those
anticipated in such statements. Investors are cautioned that
forward-looking statements are not guarantees of future performance
and accordingly investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Lorus Therapeutics Inc.'s recent press releases are available through
its website at www.lorusthera.com. For Lorus' regulatory filings on
SEDAR, please go to www.Sedar.com.
Lorus Therapeutics Inc.
Director of Finance
1-416-798-1200 ext. 372
The Trout Group
Lee M. Stern
Press spacebar to pause and continue. Press esc to stop.